In June 2021 MediSieve had a fantastic opportunity to participate in the Life Sciences RoundTable alongside Imperial College London and Novartis.
Upstream is a partnership between Hammersmith & Fulham Council and Imperial College London, a result of an Industrial Strategy co-produced by the two organisations. They have been connecting, supporting and shining a light on the science, tech and creative sectors since 2018, all driven by the belief that local networks which facilitate collaboration and learning can accelerate the growth of organisations and places. Upstream envisions to make Hammersmith & Fulham an inclusive, thriving ecosystem of ambitious science, tech and creative organisations, with the White City innovation district a global beacon of growth through innovation. Novartis is a life sciences business concerned with reimagining medicine to improve and extend people's lives, by using innovative science and technology to address some of society's most challenging healthcare issues. Novartis aims to discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible as well as reward those who invest their money, time and ideas in our company.
In June 2021, Upstream commenced a quarterly roundtable for the life sciences sector based in Hammersmith and Fulham. It brought together researchers, businesses, practitioners and academics in the life sciences space. It was the first time that many of these senior leaders had met and the energy in the room, from the outset and particularly after networking sessions was palpable. Chaired by Professor Oscar Ces, Head of Chemistry at Imperial College London, attendees range from organisations including Novartis, the MRC London Institute of Medical Sciences (LMS), Hammersmith Hospital, Autolus, DNAE, Engitix and many more. The Roundtable centred around the role of White City as London's innovation cluster. The panelists discussed what can be done and improved to boost the image, infrastructure and opportunities of the White City. The participants also shared ideas for further enhancing collaboration within the City.
MediSieve is thankful for its long lasting partnership with Upstream and the opportunities it provides. The RoundTable not only offered a chance to share ideas and future visions but to network with the community in the White City which was hard to do during lockdowns.
More about Upstream https://www.move-upstream.org.uk
About MediSieve
MediSieve is a biotech company, developing “Magnetic Blood Filtration”, a combination of a device and a therapeutic platform of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. From sepsis to malaria to leukaemia and viral infections, such as COVID-19, MediSieve has the ambition of providing hospitals with a tool to tackle some of mankind’s most serious diseases.
MEDIA CONTACT:
Alina Kagermazova
alina@medisieve.co.uk
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
george@medisieve.co.uk
MediSieve Receives Approval for First-in-Man Clinical Investigation May 24, 2022
MediSieve Receives Industry Recognition April 02, 2022